Science Explorer Back to mapMap
Discussion
Institution · Tetraphase Pharmaceuticals (United States)

Most cited papers from Tetraphase Pharmaceuticals (United States)

Tetraphase Pharmaceuticals (United States)

What are the most cited papers from Tetraphase Pharmaceuticals (United States)?

The most cited paper from Tetraphase Pharmaceuticals (United States) is "Tetracycline Antibiotics and Resistance" (Trudy H. Grossman, 2016), with 755 citations. Next come "Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial" (280) and "Resistance to Macrolide Antibiotics in Public Health Pathogens" (251).

Showing 50 of 81 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Tetracycline Antibiotics and Resistance Trudy H. Grossman · Cold Spring Harbor Perspectives in Medicine Open access 17 Mar 2016 755
2 Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial Joseph S. Solomkin, David Clay Evans, Algirdas Šlepavičius et al. · JAMA Surgery 16 Nov 2016 280
3 Resistance to Macrolide Antibiotics in Public Health Pathogens Corey Fyfe, Trudy H. Grossman, Kathy Kerstein et al. · Cold Spring Harbor Perspectives in Medicine Open access 15 Aug 2016 251
4 Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens Joyce A. Sutcliffe, William J. O’Brien, Corey Fyfe et al. · Antimicrobial Agents and Chemotherapy Open access 27 Aug 2013 239
5 IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections Joseph S. Solomkin, Jānis Gardovskis, Kenneth R Lawrence et al. · Clinical Infectious Diseases Open access 12 Dec 2018 220
6 Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic Trudy H. Grossman, Agata L. Starosta, Corey Fyfe et al. · Antimicrobial Agents and Chemotherapy Open access 21 Feb 2012 165
7 Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: A Potent, Broad Spectrum Antibacterial Agent Xiao-Yi Xiao, Diana K. Hunt, Jingye Zhou et al. · Journal of Medicinal Chemistry 9 Dec 2011 126
8 Phase 2, Randomized, Double-Blind Study of the Efficacy and Safety of Two Dose Regimens of Eravacycline versus Ertapenem for Adult Community-Acquired Complicated Intra-Abdominal Infections Joseph S. Solomkin, Mayakonda Krishnamurthy Ramesh, Gintaras Česnauskas et al. · Antimicrobial Agents and Chemotherapy Open access 17 Dec 2013 122
9 Phase I, Open-Label, Safety and Pharmacokinetic Study To Assess Bronchopulmonary Disposition of Intravenous Eravacycline in Healthy Men and Women Kevin P. Connors, Seth T. Housman, J. Samuel Pope et al. · Antimicrobial Agents and Chemotherapy Open access 28 Jan 2014 117
10 Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase Steven M. Ronkin, Michael C. Badia, S.F. Bellon et al. · Bioorganic & Medicinal Chemistry Letters 16 Mar 2010 111
11 In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii Harald Seifert, Danuta Stefanik, Joyce A. Sutcliffe et al. · International Journal of Antimicrobial Agents 11 Jul 2017 107
12 In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017 Ian Morrissey, Melanie Olesky, Stephen Hawser et al. · Antimicrobial Agents and Chemotherapy Open access 16 Dec 2019 100
13 Antibiotics in development targeting protein synthesis Joyce A. Sutcliffe · Annals of the New York Academy of Sciences Dec 2011 89
14 Consecutive reactions of aromatic-OH adducts with NO, NO 2 and O 2 : benzene, naphthalene, toluene, m- and p-xylene, hexamethylbenzene, phenol, m-cresol and aniline R. Koch, R. Knispel, Manfred Elend et al. · Atmospheric chemistry and physics Open access 25 Apr 2007 83
15 In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015 George G. Zhanel, Melanie R. Baxter, Heather J. Adam et al. · Diagnostic Microbiology and Infectious Disease 22 Dec 2017 74
16 Fluorocyclines. 2. Optimization of the C-9 Side-Chain for Antibacterial Activity and Oral Efficacy Roger B. Clark, Diana K. Hunt, Minsheng He et al. · Journal of Medicinal Chemistry 9 Dec 2011 72
17 Trends in resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States: 2013–2017 Vikas Gupta, Gang Ye, Melanie Olesky et al. · BMC Infectious Diseases Open access 23 Aug 2019 68
18 Synthesis and Antibacterial Activity of Pentacyclines: A Novel Class of Tetracycline Analogs Cuixiang Sun, Diana K. Hunt, Roger B. Clark et al. · Journal of Medicinal Chemistry Open access 18 Apr 2011 64
19 Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development Magnus Rönn, Zhijian Zhu, Philip C. Hogan et al. · Organic Process Research & Development 6 Apr 2013 62
20 Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates David R. Snydman, Laura A. McDermott, Nilda V. Jacobus et al. · Antimicrobial Agents and Chemotherapy Open access 28 Mar 2018 55
21 Development and validation of an ICP-MS method for the determination of elemental impurities in TP-6076 active pharmaceutical ingredient (API) according to USP 〈232〉/〈233〉 Osama Chahrour, John F. Malone, Mark L. Collins et al. · Journal of Pharmaceutical and Biomedical Analysis 21 Jun 2017 53
22 National prevalence estimates for resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States Vikas Gupta, Gang Ye, Melanie Olesky et al. · International Journal of Infectious Diseases Open access 20 Jun 2019 49
23 Eravacycline (TP-434) Is Efficacious in Animal Models of Infection Trudy H. Grossman, Timothy M. Murphy, Andrew Slee et al. · Antimicrobial Agents and Chemotherapy Open access 18 Feb 2015 45
24 Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline Joseph V. Newman, Jian Yi Zhou, Sergey Izmailyan et al. · Antimicrobial Agents and Chemotherapy Open access 22 Aug 2018 44
25 8-Azatetracyclines: Synthesis and Evaluation of a Novel Class of Tetracycline Antibacterial Agents Roger B. Clark, Minsheng He, Corey Fyfe et al. · Journal of Medicinal Chemistry Open access 8 Feb 2011 40
26 Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens Trudy H. Grossman, Corey Fyfe, William J. O’Brien et al. · mSphere Open access 22 Feb 2017 34
27 In vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii Harald Seifert, Danuta Stefanik, Melanie Olesky et al. · International Journal of Antimicrobial Agents 15 Dec 2019 32
28 Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers John P. O’Donnell, K. W. Lawrence, Karthick Vishwanathan et al. · Antimicrobial Agents and Chemotherapy Open access 30 Oct 2018 32
29 In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020 Stephen Hawser, Nimmi Kothari, Federica Monti et al. · Journal of Global Antimicrobial Resistance Open access 17 May 2023 31
30 Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis Abrar K. Thabit, Marguerite L. Monogue, Joseph V. Newman et al. · International Journal of Antimicrobial Agents 8 Jan 2018 29
31 Efficacy and Tolerability of Eravacycline in Bacteremic Patients with Complicated Intra-Abdominal Infection: A Pooled Analysis from the IGNITE1 and IGNITE4 Studies Vanessa Grant-Di Felice, Е. А. Ефимова, Sergey Izmailyan et al. · Surgical Infections 17 Nov 2020 28
32 Eravacycline (TP-434) Is Active In Vitro against Biofilms Formed by Uropathogenic Escherichia coli Trudy H. Grossman, William J. O’Brien, Kathryn O. Kerstein et al. · Antimicrobial Agents and Chemotherapy Open access 27 Jan 2015 28
33 Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects Jason D. Lickliter, Kenneth R Lawrence, John P. O’Donnell et al. · Antimicrobial Agents and Chemotherapy Open access 9 Apr 2020 27
34 Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits Vidmantas Petraitis, Rūta Petraitienė, Bo Bo Win Maung et al. · Antimicrobial Agents and Chemotherapy Open access 20 Jun 2018 25
35 Bayesian clinical decision support-guided versus clinician-guided vancomycin dosing in attainment of targeted pharmacokinetic parameters in a paediatric population David Michael Hughes, Srijib Goswami, Ron J. Keizer et al. · Journal of Antimicrobial Chemotherapy Open access 8 Oct 2019 22
36 Carbapenem Treatment and Outcomes Among Patients With Culture-Positive Complicated Intra-abdominal Infections in US Hospitals: A Retrospective Cohort Study Marya D. Zilberberg, Brian Harris Nathanson, Kristen L. Ditch et al. · Open Forum Infectious Diseases Open access 25 Nov 2019 21
37 In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017 Ian Morrissey, Stephen Hawser, Sibylle H. Lob et al. · Antimicrobial Agents and Chemotherapy Open access 16 Dec 2019 20
38 Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects Joseph V. Newman, Jian Yi Zhou, Sergey Izmailyan et al. · Antimicrobial Agents and Chemotherapy Open access 17 Dec 2018 20
39 Eravacycline: A New Treatment Option for Complicated Intra-Abdominal Infections in the Age of Multidrug Resistance Joseph S. Solomkin, Angie Sway, Kenneth R Lawrence et al. · Future Microbiology Oct 2019 19
40 Process Research and Development of an Enantiomerically Enriched Allyic Amine, One of the Key Intermediates for the Manufacture of Synthetic Tetracyclines Wu‐Yan Zhang, Philip C. Hogan, Chi-Li Chen et al. · Organic Process Research & Development 30 Sep 2015 19
41 Eravacycline Is Active against Bacterial Isolates Expressing the Polymyxin Resistance Gene mcr-1 Corey Fyfe, Gabrielle LeBlanc, Brianna J. Close et al. · Antimicrobial Agents and Chemotherapy Open access 23 Aug 2016 17
42 Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents Cuixiang Sun, Diana K. Hunt, Chi-Li Chen et al. · Journal of Medicinal Chemistry 30 Apr 2015 17
43 The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques Trudy H. Grossman, Michael S. Anderson, David D. Christ et al. · Antimicrobial Agents and Chemotherapy Open access 31 May 2017 16
44 Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa Yonghong Deng, Cuixiang Sun, Diana K. Hunt et al. · Journal of Medicinal Chemistry Mar 2017 15
45 A Divergent Route to Eravacycline Wu‐Yan Zhang, Qinglin Che, Scott D. Crawford et al. · The Journal of Organic Chemistry 22 Dec 2016 15
46 In Vitro Activity of TP-271 against Mycobacterium abscessus, Mycobacterium fortuitum, and Nocardia Species Michael H. Cynamon, Jeff Jureller, Balaji Desai et al. · Antimicrobial Agents and Chemotherapy Open access 15 May 2012 15
47 Synthesis and Biological Evaluation of 8-Aminomethyltetracycline Derivatives as Novel Antibacterial Agents Roger B. Clark, Minsheng He, Yonghong Deng et al. · Journal of Medicinal Chemistry 18 Sep 2013 14
48 An Evaluation of Treatment Patterns and Associated Outcomes Among Adult Hospitalized Patients With Lower-Risk Community-Acquired Complicated Intra-abdominal Infections: How Often Are Expert Guidelines Followed? Thomas P. Lodise, Sergey Izmailyan, Melanie Olesky et al. · Open Forum Infectious Diseases Open access 18 Jun 2020 11
49 Process Development and Scale-up of Fully Synthetic Tetracycline TP-2758: A Potent Antibacterial Agent with Excellent Oral Bioavailability Wu‐Yan Zhang, Cuixiang Sun, Diana K. Hunt et al. · Organic Process Research & Development 28 Dec 2015 11
50 Process Research and Development of TP-808: A Key Intermediate for the Manufacture of Synthetic Tetracyclines Wu‐Yan Zhang, Chi-Li Chen, Minsheng He et al. · Organic Process Research & Development 10 Feb 2017 10

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.